Davinder Grover
Ophthalmology · Dallas, TXNPI 1194861674
Payments from drug & device makers
Across 932 payments — averaging $1428.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$680K
- Glaukos Corporation$419K
- Reichert, Inc.$101K
- NEW World Medical,inc.$67K
- Aerie Pharmaceuticals, Inc.$28K
- Nova Eye, Inc.$20K
- plus $17K from 15 others
Across 7 payments — averaging $13,903 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$35K
- NEW World Medical,inc.$32K
- Alcon Research LLC$30K
What the payments were for
- Consulting fees$376,89253%
- Speaking & faculty fees$300,41243%
- Travel & lodging$13,3312%
- Food & beverage$14,0682%
- Gifts$2500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 530 | $679,879 |
| Glaukos Corporation | 152 | $419,295 |
| Reichert, Inc. | 56 | $100,650 |
| NEW World Medical,inc. | 59 | $66,704 |
| Aerie Pharmaceuticals, Inc. | 30 | $27,688 |
| Nova Eye, Inc. | 13 | $19,947 |
| Alcon | 51 | $7,215 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $4,826 |
| Regeneron | 2 | $2,529 |
| Thea Pharma Inc. | 6 | $1,320 |
| Mobius Therapeutics, LLC | 2 | $450 |
| Bausch & Lomb Americas Inc. | 4 | $223 |
| Biotissue Holdings Inc. | 6 | $161 |
| Novartis | 2 | $47 |
| Sun Pharmaceutical Industries Inc. | 2 | $37 |
| Akorn, Inc. | 2 | $36 |
| Oyster Point Pharma, Inc. | 1 | $27 |
| Carl Zeiss Meditec USA, Inc. | 1 | $21 |
| Sight Sciences, Inc. | 1 | $20 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
| Dompe US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$207,064
- XEN$117,544
- DURYSTA$80,835
- Ahmed Glaucoma Valve$66,446
- Kahook Dual Blade$61,571
- Rhopressa$32,505
- Rocklatan$32,505
- Clearpath$13,675
- Streamline$8,800
- Via360$8,800
- iStent inject Trabecular Micro-Bypass Stent System$5,500
- iDose$5,484
- iStent Trabecular Micro-Bypass Stent System$4,900
- VYZULTA$4,583
- TONO-VERA TONOMETER US STARTER KIT HUMAN RECHARGABLE$4,500
- iStent inject W$2,500
- Streamline Surgical System$2,250
- LUMIGAN$1,734
- Travoprost Intraocular Implant - iDose$1,600
- Hydrus Microstent$1,230
How this compares
$1,331,107 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 102 | $47,301 |
| Prednisolone Acetate | 878 | $39,691 |
| CombiganBrimonidine Tartrate/Timolol | 97 | $30,085 |
| RocklatanNetarsudil Mesylat/Latanoprost | 56 | $28,930 |
| RhopressaNetarsudil Mesylate | 33 | $18,737 |
| Latanoprost | 1,896 | $17,368 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 878 | $13,848 |
| VyzultaLatanoprostene Bunod | 35 | $13,770 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 84 | $12,483 |
| Brimonidine Tartrate | 382 | $9,781 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 35 | $9,635 |
| Pilocarpine Hcl | 160 | $9,090 |
| Timolol Maleate | 970 | $8,557 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 34 | $6,429 |
| Brinzolamide | 28 | $4,800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $679,879 | $77,386199 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $27,688 | $47,66789 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $223 | $13,77035 claims |
| AlconSimbrinza | $7,215 | $9,63535 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Dallas
- Ashkan AbbeyDallas$5.7M
- Karl CsakyDallas$4.9M
- Jeffrey WhitmanDallas$1.7M
- Oluwatosin SmithDallas$1.7M
- Robert WangDallas$594K
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.